| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3a112fa5dd8cc717ee8bdb5e4004d0b0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4419151f58c7ae749f88e2065fdd6058 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3231
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-346
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3233
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3521
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3533 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y207-11001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate |
2016-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_227a61dbad2773a2625995305da70fc3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dedbe53f0e273043225b0bbd0199bd33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6950a365bd0fcd84e6dbddb11c5619b7 |
| publicationDate |
2017-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9840710-B2 |
| titleOfInvention |
Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease |
| abstract |
The present disclosure relates generally to compounds comprising oligonucleotides complementary to a Leucine-Rich-Repeat-Kinase (LRRK2) RNA transcript. Certain such compounds are useful for hybridizing to a LRRK2 RNA transcript, including but not limited to a LRRK2 RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRRK2 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Parkinson's disease. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11332746-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11530411-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023168427-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10907160-B2 |
| priorityDate |
2015-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |